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L-THEANINE: POTENTIAL USE AS A THERAPEUTIC AGENT  
FOR PSYCHIATRIC CONDITIONS  
DAVID CHA  
ABSTRACT 
Psychiatric conditions including attention disorders, mood disorders, anxiety disorders, 
and schizophrenia pose some of the most debilitating effects on the patient population 
worldwide.  Treatments currently used to combat such illnesses have been a significant 
area of research in the medical community.  As more molecular mechanisms are 
elucidated and a deeper pathophysiologic basis is discovered for such ailments, newer 
pharmacologic modalities pave way to provide greater symptomatic relief and treatment 
with fewer side effects.  Enter L-theanine, a non-essential amino acid found in green tea 
leaves which has been touted to have anxiolytic and cognitive enhancing properties on a 
wide variety of patient demographics.  Furthermore, it has been recently studied for its 
neuroprotective qualities and antihypertensive effects.  This study delves into the current 
understanding of common psychiatric conditions, as well as providing a summary into 
the current understanding of L-theanine in its potential to a wide variety of psychiatric 
and neurologic conditions.  The apparent potential in utilizing L-theanine as a treatment 
modality is promising, and the limited studies available warrant continued research to 
provide a safe, non-toxic way in alleviating psychiatric and neurologic conditions.  
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INTRODUCTION 
 
 Psychiatric disorders are some of the most unique medical illnesses known due to 
the subjectivity of individuals in what they perceive, think, or feel1.  Defining the disease 
or disorder from a symptomatic point of view has been a conceptual dogma in describing 
and diagnosing the disease, and ascertaining key features of each illness is a dynamic 
process, with advances in each edition of the Diagnostic and Statistical Manual of Mental 
Disorders and the International Statistical Classification of Diseases and Related Health 
Problems1.  Such advances in diagnostic information help clinicians accurately diagnose 
and treat mental disease.  The subjectivity in many disorders helps one to recognize the 
exigence in understanding the biology behind Mood disorders, Anxiety Disorders, and 
Attention Deficit Hyperactivity Disorder.  These common psychiatric disorders are 
discussed and expounded upon due to the high prevalence and co-morbidities of these 
disorders in the United States and worldwide.  
 
 
 
Major Depressive Disorder: A Worldwide Health Problem 
 
Major Depressive Disorder (MDD) is one of the most common psychiatric 
disorders worldwide and its prevalence is evident by the multitude of pharmacological 
agents available to treat the condition2.  Understanding the etiology of MDD has been an 
extensive and substantial area of scientific research in the medical community.  The 
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complexity of its causation from a biological standpoint has proved to be difficult due to 
the intricate nature of overlap involving genetic and environmental factors3. 
 
Monoamine Hypothesis: The First biological theory of Depression 
 
Mechanistic theories to elucidate the biological cause of depression originated 
with the Monoamine Hypothesis.  During the discovery of a potential new drug to treat 
tuberculosis in the 1950s, iproniazid, it was observed that patients had an uplifted mood 
and became inappropriately happy4.  Additionally, the use of an alkaloid, reserpine, used 
for treatment for hypertension and psychotic symptoms, would induce depressive-like 
symptoms in certain patients5.  These unexpected side effects helped to shed light onto 
the biological mechanisms which would contribute to the understanding of the 
pathophysiology of MDD.   
The basis of the monoamine hypothesis is that a chemical imbalance of 
monoamines, norepinephrine, dopamine, and serotonin, have a direct effect in 
potentiating mood disorders6.  For example, a deficiency of norepinephrine can lead to 
depression, likewise, an excess of norepinephrine can induce mania6.  Such an imbalance 
of these monoamines provides the basis of the monoamine hypothesis in elucidating the 
underlying pathophysiology of major depressive disorder6.  Iproniazid, a non-selective, 
irreversible monoamine oxidase inhibitor, could induce manic symptoms due to an excess 
of monoamines7, whereas reserpine, which irreversibly blocks the vesicular monamine 
transporter, VMAT, could induce depressive like states in patients8.  
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Anecdotal evidence of the side effects of these early pharmacotherapies paved 
way to produce the first pharmacologic agents, monoamine oxidase inhibitors (MAOI), 
which were approved to treat MDD4.  The treatment of depression with a specific 
pharmacologic agent proved to be helpful in alleviating depressive symptoms, however, 
the dietary interactions and side effects associated with MAOIs, specifically foods and 
beverages with a high tyramine content such as wine and cheese, could cause a 
hypertensive crisis in patients9.  Tyramine, as a pressor amine, would exacerbate the 
sympathetic pressor response and potentiate a hypertensive crisis9. 
 
Tricyclic Amines 
 
The next class of medications which were used to treat depression were the 
tricyclic antidepressants (TCA).  During the time in which neuropharmacology research 
was experiencing rapid growth and discovery, the development of a drug by the French 
chemist Paul Charpentier developed chlorpromazine, which was one of the first widely 
used antipsychotic drugs.  Chlorpromazine is used currently as an antipsychotic to treat 
schizophrenia, and its utility for clinical therapy prompted the further discovery of other 
derivatives of chlorpromazine.  This led to the first TCA used to treat MDD, imipramine, 
which was not initially developed for the condition.  Clinical observations of manic 
effects in patients paved way for it to be tested on depressed patients. 
 
 Although MAOI’s and TCA’s were some of the front-line medications in  
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pharmacologic advancement in the treatment of mood disorders in the 1950’s and 1960s, 
the widespread non-selective pharmacodynamic effects, side effect profile, which 
included the lowering threshold of seizures10, and high potential for toxicity with food 
interactions, prompted researchers to ascertain and hone on a new class of medications 
which would have a lower side effect profile, did not have such a stringent diet 
restriction, and didn’t exhibit such broad, non-selective effects11. 
 
 
 
Selective Serotonin Reuptake Inhibitor: Pharmacologic Breakthrough in Treatment  
 
of Mood Disorders with Selective Action 
 
Selective serotonin re-uptake inhibitors (SSRI) were developed in the 1970s in 
response to the unfavorable side effect profile and dietary interactions associated with 
MAOIs and TCAs11.  The development and discovery of SSRIs were a pharmacologic 
breakthrough, for many reasons.  First, they were the first to validate the principal role of 
the inhibition of a neurotransmitter re-uptake as a therapeutic modality11.  Second, SSRIs 
paved way to provide evidence that Serotonin (5-HT) has a central, pathophysiologic role 
in mediating the causality and severity of affective and mood disorders.  Third, SSRIs 
were the first class of medications in the treatment of mood disorders developed through 
rational design.  Meaning, the development of a new pharmacologic agent with intention 
of effecting a known biological target12. 
 
 SSRIs are used to treat a variety of mood disorders including major depressive 
disorder (MDD), obsessive compulsive disorder (OCD), premenstrual dysphoric disorder 
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(PMDD), panic disorder, and social anxiety disorder11.  They are currently recommended 
as a first-line agent in treating MDD by the National Institutes of Health, with less of a 
side effect profile than MAOIs or TCAs10.  Some examples include citalopram, 
escitalopram, fluoxetine, paroxetine, and sertraline.  
 SSRIs were a breakthrough in pharmacologic research because of their selectivity 
in inhibiting the serotonin transporter, with negligible effects on the dopamine transporter 
or norepinephrine transporter.  Inhibition of the 5-HT binding to the serotonin transporter 
increases the concentration of 5-HT in the synaptic cleft, increasing postsynaptic receptor 
binding of 5-HT receptors, manifesting as an alleviation of depression symptoms13.  
 It is interesting to note that although noticeable increases of 5-HT in the synaptic 
cleft can be experimentally observed soon after one starts the medication, it usually takes 
a few weeks to alleviate the symptoms and receive the clinical benefit and therapeutic 
effect of SSRIs13.  One possible explanation is that although SSRIs increase the amount 
of 5-HT in the synaptic cleft by binding to the serotonin transporter and subsequently 
prevent degradation and metabolism in the presynaptic neuron by MAOI, the increased 
amount of 5-HT leads to a desensitization of the 5-HT1A autoreceptors on the presynaptic 
neuron.  This desensitization of the autoreceptor increases the impulse flow of 5-HT 
leading to an enhanced release and greater aggregate of 5-HT in the synaptic cleft.  
Desensitization of the autoreceptors takes some time compared to the noticeable increase 
of 5-HT soon after taking SSRIs, which is thought to be the main reason for the 2-3 week 
delay in observing therapeutic effects of SSRIs13. 
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Serotonin-Norepinephrine Reuptake Inhibitors 
 
 Serotonin-norepinephrine reuptake inhibitors (SNRIs), like SSRIs inhibit the 
reuptake of Serotonin Transporter, but additionally inhibit the reuptake of norepinephrine 
transporter (NET)14.  As a result, the pharmacologic effect of inhibiting the reuptake of 
both the SERT and NET have possibly contributed for using SNRIs to not only treat 
mood disorders, but also its utility in treating other conditions such as Attention Deficit 
Hyperactivity Disorder (ADHD), Fibromyalgia, Generalized Anxiety Disorder (GAD), 
and Post Traumatic Stress Disorder (PTSD)15. 
 
 
 
Norepinephrine Reuptake Inhibitors 
 
 Norepinephrine reuptake inhibitors inhibit the action of the NET transporter, thus 
increasing concentrations of Norepinephrine and Epinephrine in the synaptic cleft.  This 
is manifested as an increase in adrenergic transmission, and has been favorably used in 
the treatment of ADHD, Anxiety Disorders, MDD, Panic Disorders, and Narcolepsy due 
to its sympathomimetic effects.  Since NRI medications do not affect the dopamine 
reuptake inhibitor (DRI), these class of drugs do not have the potential of abuse as other 
drugs that inhibit both the NRI and the DRI16. Some drugs in this class include 
atomoxetine and bupropion, which are FDA-approved to treat ADHD and Depression, 
respectively.  
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Etiology of Anxiety  
 
          Anxiety is an emotion described as an unfavorable state of inner dissonance, and 
often manifested with nervous behavior, in which one anticipates pending danger or 
threat.  It is a complex emotion in which the individual subjectively perceives a 
circumstance or situation as overly threatening, and the accompanying behavior can 
include fatigue, restlessness, problems concentrating, and muscular tension. Although 
some level of anxiety is considered normal, when it is pathologically over-experienced by 
the individual, he or she may be suffering from an anxiety disorder17.  
 
 
Biological Origins of Anxiety  
 
There is much scientific evidence which provides information on the biological 
origins of anxiety.  From an anatomical perspective, the amygdala, which regulates 
emotions like anxiety and fear, and the hippocampus, which processes emotional 
memory, are thought to be the main contributors to anxiety18.  From a biochemical level, 
the neurotransmitter g-aminobutyric acid (GABA) plays a central role in the 
pathophysiology of anxiety and anxiety disorders19.  
 
GABA is a primary inhibitory transmitter in the central nervous system (CNS) of 
mammals, modulating neuronal excitation in the CNS20.  Derived from the amino acid 
glutamate through glutamate decarboxylase, GABA functions as an excitatory 
neurotransmitter during the neonatal stage of brain development, whereas it functions as 
an inhibitory transmitter in the adult brain21.  The switch from an excitatory to an 
inhibitory NT is influenced from the concentration of chloride ions in the brain.  When 
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the neuronal chloride concentration is at a high level, GABA acts as a excitatory NT, and 
as it decreases to a certain level it acts as an inhibitory neurotransmitter21.  Chloride 
concentration is modulated by the Na+K+Cl-Cl- cotransporters (NKCC), with NKCC1 
increasing chloride concentration and NKCC2 decreasing chloride concentration19.  
GABA is also known to have a crucial role in the developing brain acting in both an 
autocrine and paracrine fashion22.  Although for many years it was known that glutamate 
is the primary excitatory NT and GABA is the primary inhibitory transmitter in the adult 
brain, recent evidence has shown that both NT’s are important in modulating embryonic 
development of the brain23.  Glutamate and GABA mediate their action through 
activation of ionotropic (ligand gated ion channels) and metabotropic (G-protein coupled) 
receptors23.  
The variety of subclasses of ionotropic glutamate receptors are named after the 
agonists 1) α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)  2) N-
methyl-d-aspartate (NMDA) 3) kainate receptors 24.  The metabotropic glutamate 
receptors are known to have at least eight different subtypes based on homology of their 
sequence and transduction pathways25.  Group I comprise of mGlu1, mGlu5 and their 
splice variants (mGlu1α, β, c, d and mGlu5a,b); group II receptors include mGlu2 and 
mGlu3; and group III consists of mGlu4, mGlu6, mGlu7 and mGlu8, and some splice 
variants23.  The GABA ionotropic receptors, GABAA receptors, display even more 
diversity in their composition with eight subunit families 21 subclasses.  The 
metabotropic G coupled protein GABA receptors (GABAB receptors) have 2 subunits of  
GABAB1 and GABAB2 . 
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Figure 1: The different classes and subtypes of Glutamate and GABA receptors 
Hollmann M, Heinemann S. Cloned glutamate receptors 
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Pharmacologic Agents of Anxiety 
Specific pharmacologic agents possessing anxiolytic effects have helped hone in 
on the molecular mechanisms which contribute to anxiety.  Specifically, benzodiazepines 
and barbiturates, with known anxiolytic effects, have allowed researchers to ascertain 
specific molecular receptors which help explain a neurobiological basis for anxiety.  
 
Benzodiazepines  
A class of medications known as benzodiazepines (BZD) has been around since 
the 1960’s, and has been used as therapeutic agents for alleviating anxiety26.  Such 
pharmacologic agents increase the amount of GABA, and clinical observations have 
shown that BZDs have positively therapeutic effects of anxiolytic and anti-convulsive 
effects27.  BZDs have been paramount agents of clinical utility, still being currently used 
for treatment of anxiety disorders, insomnia, and as a sedative28.  
BZDs allosterically potentiate the GABAA receptor, dually increasing the amount 
of GABA and potentiating its effects, decreasing the excitability of neurons, which is 
correlated with the anxiolytic effects associated with BZDs28.  The GABAA receptor 
allows chloride ion influx resulting in hyperpolarization of the neuron, causing an 
inhibition of neurotransmission and neuronal activity19.  It is interesting to note that 
BZD’s do not decrease the Km of GABA binding to the GABAA receptor as other 
positive allosteric modulators do, but rather by increasing the conductance of Cl ions 
across the cell membrane when GABA is already bound. The increased conductance  
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hyperpolarizes the neurons and decreases excitability through increasing the gap 
of resting membrane potential and the threshold potential29. 
 
Although BZDs are common in their short-term use to treat anxiety and insomnia, 
long-term use of BZDs have been associated with negative health effects and risks30.  
Physical dependency of BZDs can develop and individuals who have taken BZDs for a 
considerable amount of time. Such patients need to be tapered off dose to prevent 
physical and mental withdrawal symptoms, often manifested as tremors, dizziness, 
irritability31.  Such physical dependence can occur only after a few weeks of use, and 
studies have shown the utility of mood stabilizing medications to help attenuate negative, 
adverse withdrawal effects with discontinuing BZD use in patients who have been 
prescribed BZDs for a considerable amount of time32. 
Additionally, long term use of BZDs have been shown to cause a decline 
cognitive function, manifested as memory problems (anterograde and retrograde 
amnesia), attention deficits, and psychomotor dysfunction33.  These effects on cognition 
can exacerbate the decline in cognitive dysfunction, especially in elderly patients34.  
Although the deficits in cognitive function associated with long-term use are often 
reversible with improvement to baseline function, often times such decline in cognition 
can be permanent35.  Thus, the long-term impact on cognition is not clear and must be 
taken into consideration when prescribing such medications, and particularly in the 
elderly35.  Such improvements of returning cognition to baseline function are most 
noticeable after 6 months, but often take a few years to improve35. 
 The decline in cognitive function associated with elderly patients poses a 
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significant concern, as many elderly patients are on antihypertensive medication not only 
affects the cholinergic system, but also can potentiate symptoms of ataxia, vertigo, and 
fatigue associated with orthostatic hypertension36.  One of the biggest concerns for BZD 
use in the elderly is that such side effects of ataxia and vertigo can increase the chances 
of falls, which are potentially dangerous37.  Furthermore, concurrent treatment with 
BZD’s and antihypertensives has been associated with a strong correlation of drug-
induced dementia in the elderly38.  Fortunately, studies have shown that cessation of BZD 
use in the elderly who use the medication for treatment of insomnia restores psychomotor 
function and improves cognition, while not exacerbating the insomnia39.  Such evidence 
requires prescribers to consider and acknowledge the long-term effects of BZD use, and 
recognize that the utility of treatment of anxiety and insomnia with BZDs is best used as 
a short-term pharmacologic agent.  
  
 
 
Barbiturates 
 
              Barbiturates are derivatives of barbituric acid and are pharmacologic agents 
primarily used as anesthetics, anticonvulsants, and analgesics40.  Although they possess 
anxiolytic and hypnotic qualities, their potential for side effects and lethal overdose has 
greatly decreased their use as an anxiolytic in preference of benzodiazepines for short-
term treatment of anxiety and insomnia41.  Thus, their main utility in current clinical 
application is as an anticonvulsant and as an anesthetic42. 
Like BZDs, barbiturates potentiate the effects of GABA on the CNS.  Barbiturates 
are allosteric modulators of the GABAA receptor, but at higher doses, they can act like as 
 13 
a direct agonist of the GABAA receptor
43.  The binding sites of barbiturates to ionotropic 
GABAA receptors are distinct from the binding sites of BZDs
43.  Like BZDs, the effects 
of allosteric modulation of the GABAA receptor potentiates the effect of GABA once 
bound to the GABAA receptor
44.  It is interesting to note that BZDs increase the 
frequency of the GABAA receptor receptor from opening the chloride ion channel, 
whereas barbiturates can prolong the opening of the chloride ion channel45.  This is 
referred to as increasing potency of GABA for BZDs and increasing the efficacy of 
GABA for barbiturates.  
Not only do barbiturates increase the efficacy of GABA, leading to a prolonged 
state of chloride conduction, but at higher doses, barbiturates can directly open the 
chloride channel in the absence of GABA binding.  Furthermore, at increased 
concentrations of barbiturates, they also have an inhibitory effect on AMPA and kainate 
ionotropic glutamate receptors, leading to a synergistic effect of barbiturates having an 
enhanced effect on CNS depression than BZDs, which only have an effect on the GABAA 
receptor45.  Lastly, at higher concentrations of barbiturates, as often used during the 
induction phase of anesthesia, they can modulate the calcium dependent release of 
glutamate through its effects on P/Q type voltage-dependent calcium channels45.  These 
widespread effects of barbiturates including allosterically modulating GABAA receptors, 
acting as a direct agonist of GABA, acting on AMPA and kainate receptors, and 
modulating release of the excitatory transmitter glutamate facilitate the much stronger 
effect of barbiturates causing CNS depression than BZDs45.  Thus, prescribers need to be 
much more cognizant when dosing barbiturates due to potential of lethal overdose45.  
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Etiology of ADHD 
 
 Attention deficit hyperactivity disorder is a complex, neurodevelopmental 
disorder which is defined as one having as attentional and neurocognitive deficits, 
specifically with problems regarding attentional control, working memory (known as 
executive function), as well as hyperactive and impulsive behavior.  This disorder is 
estimated to affect more than 30 million people46.   
One of the challenges in understanding the etiology and diagnosis of ADHD is 
that there are no laboratory or conclusive phenotypical tests to confirm the diagnosis.  
Additionally, there are often other disorders that have overlap of symptomatic features 
that can make differentiating a conclusive diagnosis particularly challenging.  This is 
even further complicated by the fact that individuals who have ADHD often have co-
morbidity of other psychiatric disorders, such as anxiety disorders, mood disorders, 
narcolepsy, obsessive compulsive disorders, and sleep disorders47.  ADHD is often 
known to have a significantly higher rate of diagnosis in boys than girls48. 
It has been suggested that there are complex environmental factors involving 
social and behavioral facets as well as genetic predispositions associated with the 
condition.  As a result,  
 
the diagnosis and its treatments are a controversial topic in the medical community49.  
Nevertheless, the associated prevalence and impact of ADHD in the pediatric and adult 
patient population is indeed real, as it is estimated to affect close to 10% of the pediatric 
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patient population and that almost half of the pediatric patient population affected pose a 
significant chance of having the disorder throughout his or her life50.  Furthermore, 
conclusive diagnoses of ADHD are difficult and may be underdiagnosed, as individuals 
with higher cognitive functioning may be able to mask the symptoms of ADHD through 
performance in academic, personal, and social lives that are on par with what is 
associated as a normal range51. 
 
 
 
The Complex Task of Differential Diagnosis with ADHD  
 
 One of the challenges in differentiating a diagnosis of ADHD from other mood 
and panic disorders is that many of the symptoms are often identical, which often may 
complicate the ability in giving a conclusive diagnosis52.  Specifically, mood and panic 
disorders such as anxiety, depression and bipolar disorder often display an overlap and 
similarity of symptoms52.  Such overlap could potentially lead to the condition being 
underdiagnosed or even possibly overdiagnosed.  In the United States and Canada, the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV or DSM-V) is primarily 
used to diagnose patients, while in Europe, the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) is used53.  It is interesting to note that a 
diagnosis of ADHD is four times more likely using the DSM-IV criteria than with the 
ICD-10 manual53.  Thus, an accurate differential diagnosis is paramount when 
ascertaining the condition and any associated overlap of symptoms.  Even known medical 
conditions not necessarily related to the biologic or physiologic etiology of ADHD can 
produce symptoms very similar to ADHD54.  For example, symptoms of low self-esteem, 
 16 
irritability, and mood swings can occur from abnormalities of the thymus; cyclothymia 
and dysthymia are known to precipitate such symptomatic behavior54.  Furthermore, 
personality disorders such as antisocial personality disorder and borderline personality 
disorder have been observed to display an overlap of symptoms as well54. 
  
  
  
Co-Morbidities Associated with ADHD  
 
There is a significant proportion of individuals having co-morbidities of learning, 
mood, panic, and personality disorders with ADHD.  One German study by Walitza et al. 
found that the majority (66%) of children who have ADHD are co-morbid for other 
disorders as well47. Although ADHD is not considered a learning disability, it has been 
found to occur in close to one-third of the pediatric patient population who have been 
diagnosed with ADHD47.  Behavior disorders, such as Oppositional Defiant Disorder 
(ODD) and Conduct Disorder, display a significant association of co-morbidity with 
ADHD55.  Additionally, Tourette syndrome has a higher incidence within the ADHD 
population55. 
 Not only is the diagnosis of ADHD difficult due to the overlap of similar 
symptoms with anxiety disorders and mood disorders, but there is a profound incidence 
of co-morbidity with anxiety disorders, mood disorders, and substance use in individuals 
with ADHD56.  Childhood behavior disorders such as ODD and CD often times manifest 
throughout adulthood as antisocial disorders in individuals suffering from ADHD56. 
 Symptoms of anxiety increase the complexity of differential diagnoses due to the 
similarity of overlap of symptoms in anxiety disorders as well as ADD, and without a 
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doubt there are increased rates of co-morbidity of generalized anxiety disorder and social 
anxiety disorder with individuals who have ADHD56.  An increased incidence of 
individuals who have ADHD having co-morbidity with MDD by two-fold suggests a 
strong correlation of individuals with ADHD developing a depressive disorder in his or 
her life56. There is evidence that pre-adolescent males diagnosed with ADHD have a 
higher disposition in developing a mood disorder or bipolar disorder or MDD56 
 Substance Use Disorders are prevalent amongst individuals who have ADHD.  In 
particular, adolescents are at twice the risk for nicotine dependence than their peers 
without ADHD56.  The early exposure of adolescents to cigarette use is known to be a 
gateway to further alcohol and drug use, and this increased risk is potentiated with 
adolescents with ADHD57, as they pose a stronger chance in developing nicotine 
dependence than non-ADHD individuals58.  Furthermore, individuals with ADHD tend to 
develop a stronger physical and psychological dependence on nicotine and tend to sustain 
their addictions for a longer period compared to their non-ADHD cohorts59.  In a sense, 
individuals with ADHD may be self-medicating their condition to improve cognition and 
focus, and their dependency on nicotine may be a way of coping with co-morbid mood 
and anxiety disorders.  
 
 
 
Biology of ADHD 
  
Genetics 
 
 The prevalence of ADHD worldwide has been estimated at roughly 5%57.  Family 
studies show evidence of a strong genetic factor in the etiology of ADHD. Although the 
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complexity of the development of ADHD is multi-factorial - both from a genetic 
standpoint as well as an environmental one, much of the empirical evidence shows that 
having a family history of ADHD increases the risk of the individual in manifesting the 
disorder57.  Twin and adoption studies prove a strong correlation of genetic predisposition 
of ADHD, with a greater similarity for ADHD and its genetic components between 
monozygotic twins vs dizygotic twins5660.  The apparent association of the strong genetic 
component of ADHD is further validated through 20 extant twin studies which estimate 
the heritability (h2) of one obtaining ADHD to be 75-91%60. Additionally, the estimated 
risk of parents with the disorder when having children with ADHD is two to eight fold, 
after controlling for gender and socioeconomic status61.  Without a doubt, relatives of 
individuals with ADHD are at a higher risk, and ADHD is thought to be one of the most 
widely recognized psychiatric disorders with a genetic component56. 
 
 The polygenetic nature of ADHD is confirmed by studies of the dopaminergic 
neurotransmission genes related to Dopamine D4 Receptor (DRD4), Dopamine D5 
Receptor (DRD5), Dopamine Transporter (DAT1), Dopamine Beta Hydroxylase (DBH), 
and serotonergic transmission system genes affecting the Serotonin Transporter gene 
(SERT), Serotonin HTR1B receptor (HTR1B), and systems affecting neuronal plasticity 
and modulation, the Synaptosomal-Associated Protein 25 (SNAP-25)60. 
 
Pathophysiology of ADHD: Dopamine Hypothesis  
 Like mood disorders, it seems that the imbalance and dysregulation of 
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catecholamine neurotransmission plays a significant role in the pathophysiology of 
ADHD56.  The concept of understanding the neurobiology of ADHD has developed a 
hypothesis that ADHD is mainly a disorder with deficits in executive function – cognitive 
abilities related to attentional control, cognitive flexibility, inhibitory control, and 
working memory62.  The main part of the brain that seems to be primarily involved in 
executive function is the frontal lobe56.   
 Neurotransmission of dopamine is implicated in most studies, and also provides 
the basis of the strong genetic component of ADHD when comparing studies involving 
dopaminergic transmission, specifically the DRD4, DRD5, DAT, and DBH6063.  
Dopamine pathways originating in the locus coeruleus and ventral tegmental area, which 
then project to the frontal cortex, are responsible for the modulation of executive 
function, as well as motivation, voluntary motor function, and the perception of reward64. 
The basis of the dopamine hypothesis in the pathophysiology of ADHD was 
provided by the initial observation of psychostimulants in the laboratory65.  
Psychostimulants, which increase extracellular dopamine concentrations in the neuronal 
synaptic cleft, often had a calming effect, attenuating hyperactive symptoms and inability 
to focus66.  This was somewhat of a paradox, as using stimulants to treat hyperactivity 
lead to a reduction of ADHD symptoms, rather than increasing them.  For example, DAT 
knockout mice, which displayed hyperactive symptoms, responded to acute 
methylphenidate (MPH) treatment, and alleviated ADHD symptoms66.  MPH binds and 
blocks DAT and NE transporters, functioning technically as a NDRI, with a stronger 
effect on DAT67.  The enhanced effect of MPH modulating the levels of dopamine in the 
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synaptic cleft with a corresponding profound alleviation of ADHD symptoms allowed the 
medical community to obtain greater detail on the dopamine hypothesis and the utility of 
psychostimulants in the treatment of ADHD68. 
 Removal of DAT has profound implications on neuronal effects and activity.  
Since DA levels in the synaptic cleft are primarily regulated by the DAT, studies with 
knockout mice having no DAT showed profound effects in cognition, including 
hyperactivity and motor dysfunction69.    
 Studies on the pharmacodynamic effects of psychostimulants as a viable treatment 
for ADHD recognized the utility in increasing dopamine levels in the PFC as a way of 
attenuating symptomatic behavior of the disorder68.  Nevertheless, it was still considered 
a paradox to treat hyperactive patients with stimulants.  The basis of the approval and 
utility as a viable ADHD treatment, as with the discovery of many psychotropic agents, 
was that by exhibiting a favorable clinical response in treating the symptoms of the 
disorder, there was clinical justification for the use of psychostimulants in the treatment 
of child and adult patients with ADHD69.   
Further research is warranted to delve into the specific mechanisms involving the 
pharmacodynamic effect of psychostimulants.  For many years, the central dogma in 
understanding the mechanistic effect of stimulants, such as methylphenidate, in the 
treatment of ADHD was that the increased levels of DA in the synapse as a result of 
binding to the DAT led to a decrease in hyperactive symptoms and an increase in focus – 
providing a paradoxical calming effect and alleviating ADHD symptoms.   
What is interesting to note is that in DAT knockout mice, where there was an 
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overwhelming increase in the levels of DA, the administration of methylphenidate would 
also alleviate such hyperactivity, although mice had already substantially higher amounts 
of DA in the synaptic cleft prior to administration.  This led to the development of 
another important facet in the theorized pathophysiology of ADHD, involving the 
neurotransmitter serotonin, 5-HT.  
 
 
Serotonin Modulation: Role in ADHD 
 
 Serotonin, or 5-hydroxytryptamine, (5-HT), is a monoamine NT derived from the 
amino acid tryptophan. It is mainly found in the gastrointestinal tract of enterochromaffin 
cells, where it regulates gastrointestinal motility and digestion70.  It is also found in blood 
platelets where it regulates clotting with its release70.  Lastly, it is found in the CNS and, 
like DA and NE, functions in neurotransmission70. It is a known modality in 
pharmacotherapeutics in the treatment of mood disorders such as MDD and panic 
disorders such as GAD.  Recently, studies have suggested that serotonin may be 
implicated in modulating dopaminergic neurotransmission as well.  
 
 For many years, a large majority of the research into the pathophysiology of 
ADHD was directed towards understanding more about dopamine and its role in CNS  
neurotransmission. This could be attributed to the success of methylphenidate in treating 
the disorder, in which its apparent effects on dopaminergic neurotransmission through the 
inhibition of DAT was thought to normalize deficient levels of DA leading to a reduction 
in hyperactivity and improvement of symptomatic behavior associated with ADHD71.   
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 Although methylphenidate is classified as a dopamine-norepinephrine reuptake 
inhibitor (NDRI), the pharmacodynamics of methylphenidate shows a receptor binding 
profile of the SERT, 5HT1A, and 5HT2B as well
72.  One of the paradoxical studies that 
helped contribute to the theory of serotonin modulation in its role in the development of 
ADHD was the evidence that the use of methylphenidate led to the attenuation of 
hyperactive symptoms in mice who lacked the DAT transporter, in which 
methylphenidate did not noticeably change any levels of DA in the knock-out mice69.  
This was not observed in the wild-type mice, despite the similar effect of a non-
substantial change in DA levels as the knock-out mice71.  This study provided insight into 
the role of serotonin in modulating the development of dopaminergic transmission and 
thus the development of ADHD71.  
 
 The serotonergic and dopaminergic systems have been shown to not be mutually  
exclusive73.  Administration of the SSRI, citalopram, has shown changes in extracellular 
striatal dopamine concentrations through the use of positron emission tomography73.  
Additionally, the use of a 5-HT antagonist, altanserin, has shown to modulate DA in 
freely-moving rats through measurement of in vivo microdialysis73.  Since it is 
understood that the intricate overlap of dopaminergic and serotonergic neurotransmission 
modulate and influence each other in the CNS, the dynamic interaction of both NT’s in 
synaptic transmission infers a validation in the dopamine hypothesis in the biological 
origin of ADHD, as well as affirming the argument of serotonergic modulation in 
influencing the pathophysiology of ADHD71. 
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 Much evidence exists that the serotonergic system exerts both a phasic and tonic  
inhibitory control of the mesocorticolimbic dopaminergic system originating from the 
VTA74.   The utility of the serotonergic system as a modality in dopaminergic function 
provides a potential therapeutic option in the treatment of disorders not necessarily only 
involving 5-HT, but DA as well.  Interestingly, the complexity of the intricate overlay 
and interaction of the dopaminergic and serotoningeric sytems can be validated by 
evidence that the 5HT1B receptor functions dually as a presynaptic and postsynaptic 
autoreceptor75.  Furthermore, the 5-HT1B receptor functions as a heteroreceptor as well, 
influencing NT release from non-serotonergic nerve endings75.  
  
 
L-Theanine: Synthesis and Occurrence 
 
 L-theanine, also known as L-γ-glutamylethylamide and N5-ethyl-L-glutamine, is a 
non-essential amino acid found naturally in tea plants76.   It is what is thought to give 
green tea its delicate, organic flavor, and also activates umami receptors, which are 
thought to give a tingling and pleasant sensation of the palate, contributing to the flavor77.  
Although it is found in some fungal species, it accounts for up to 50% of the amino acids 
in green tea, and thus a major determinant of the quality of tea leaves76. 
 
 The species of tea plants in which L-theanine exist include the Camellia sinensis, 
known for its leaves in making green tea.  Additionally, it has been found in fungal 
species, including the Xerocomus badius76.  In the species C. sinensis, L-theanine is 
synthesized from L-glutamic acid and ethylamine to produce L-theanine via L-theanine 
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synthetase.  Ethylamine is produced by L-alanine by L-alanine decarboxylase.   Like 
other alpha-amino acids, theanine possesses chirality, and since L-theanine is naturally 
produced in C. sinensis from L-glutamic acid, it is the L-theanine enantiomer that is 
found readily available in tea plants.  
 
 
 
 
Figure 2: Structure of L-theanine and D-Theanine 
Mu W, Zhang T, Jiang B. An overview of biological production of L-theanine. 
Biotechnol Adv.  
 
  
 
 
Figure 3: Biosynthetic pathway of L-theanine proposed in Camellia sinensis 
Mu W, Zhang T, Jiang B. An overview of biological production of L-theanine. 
Biotechnol Adv.  
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Pharmacokinetic Properties of L-Theanine 
 
 The pharmacodynamic property of L-theanine of crossing the blood - brain barrier 
was first reported from Terashima et al78.  The study showed that concentrations of L-
theanine increased in serum, liver and brain up to 1 hour after administration, and 
subsequently after the first hour, dramatically declined in the serum and hepatic 
circulation, but concentrations in brain tissue steadily remained until 5 hours after 
administration, when its levels began to decrease7879. Terashima et al. proposed the route 
by which L-theanine was incorporated in the CNS, crossing the blood brain barrier 
through the leucine-preferring transport system79.  When L-theanine was administered 
introperitoneally, experiments by Kimura and Murata showed that L-theanine was taken 
up by brain tissue in little as 30 minutes80.  L-theanine seems to have a significant half 
life, as concentrations decrease at a gradual rate during a 24 hour period79. 
 
 
 Studies have shown that L-theanine is absorbed primarily in the gastrointestinal 
tract, through the use of Na-coupled active transporters on the brush border membrane in 
a mechanism similar to glutamine, with a peak absorption of about 0.5-2 hours 8182.  
Animal studies have shown the enantiomeric selectivity of L-theanine vs D-theanine in 
vivo. When measuring plasma theanine concentrations via oral administration, there was 
a significant decrease in gastrointestinal absorption of D-theanine compared to the 
psychoactive L-theanine.  
  
 L-theanine tended to be preferentially reabsorbed and metabolized by the kidney, 
whereas D-theanine was actively and preferentially secreted, unmetabolized in the 
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urine82.  Not much is known about the specific metabolic effects, as it seems that L-
theanine is primarily metabolized by the kidney and mostly excreted, with little change in 
plasma concentrations of its metabolites.  The proposed mechanism is the hydrolysis of 
L-theanine to ethylamine and glutamic acid in the kidneys by phosphate-independent 
glutaminase, as the kidney is one of the most effective sites of hydrolysis for its 
metabolism to glutamic acid and ethylamine83. 
 
 
 
Toxicity 
 
 Studies on the toxicity of L-theanine have shown little or no adverse effects on 
rats which were administered daily dietary doses of 1500-4000mg/kg/day for atleast 13 
weeks84.  Clinical pathology on microscopic and macroscopic levels found L-theanine not 
to adversely affect male and female rats, even at such profoundly high dosages84.  
Borzelleca et al. concluded that dose-dependent treatment of L-theanine did not produce 
any adverse toxic effects on parameters measured, including a 78-week chronic 
toxicity/carcinogenicity study and a negative Ames test84.  It was concluded through his 
study that no adverse effects were related to the chronic administration of L-theanine up 
to 4000mg/kg/bw/day84.  
 
 
 
Effects of L-Theanine on Neurotransmission 
 
 Since L-theanine is derived from the excitatory NT glutamate, the overlap of 
pharmacologic effects of L-theanine in dopaminergic neurotransmission seems plausible.  
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Studies have reported the effects of L-theanine on neurotransmission in which, after only 
30 minutes of administration, L-theanine could modulate the release and functionality of 
NTs81.  A dose-dependent increase of nigrostriatal dopamine release in rats after oral 
administration and direct injection of L-theanine has been shown, in which the 
mechanism proposed in dopaminergic modulation is from Ca++ release from L-theanine 
stimulation of NMDA receptors81.   
 
 Studies from Yokogoshi et al. showed that NE neurotransmission may not be 
affected to the same extent that dopaminergic and serotonergic transmission is 
influenced85. Their study hypothesized that L-theanine may exhibit selective modulation 
on dopaminergic and serotonergic neurons, as there were substantial increases in both 5-
HT and DA in the hippocampus, hypothalamus, and nigrostriatal regions, with little 
change in the levels of NE85.   
 
Furthermore, L-theanine exhibited, in a dose-dependent manner, increases of 
dopaminergic neurotransmission when administered directly to the nigrostriatal region 
via microinjection85.  Interestingly, the use of an antagonist of the NMDA glutamate 
receptor, (+/-)-2-amino-5-phosphonopentanoic acid (AP-5), dramatically inhibited DA 
release after L-theanine administration, possibly alluding that a significant modality in 
which L-theanine influences dopaminergic transmission may be through the action of the 
NMDA glutamate receptor85.  
 
 Another study by Yokogoshi et al. provided insight into the modulation of L-
theanine on serotonergic neurotransmission.  In rats, intragastric administration of L-
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theanine was shown to substantially increase the concentrations of the 5-HT precursor, 
tryptophan, in the brain86.  Paradoxically, L-theanine had the effect of attenuating 5-HT 
concentrations, although it would increase tryptophan levels86.  Although elucidating the 
significance of these findings proved to be difficult, there was a steady dose-dependent 
relationship of L-theanine and an increase in the precursor amino acid tryptophan and 
decrease in 5-HT86.  Yokogoshi et al. also pointed that there was interesting evidence that 
tryptophan influenced 5-HT concentrations in the CNS by a mechanism called precursor-
mediated control of NT, further validating the intricate nature of overlay between 
feedback-inhibition and overlap of serotonergic and dopaminergic neurotransmission86.  
It is also thought that L-theanine modulates glutamate reuptake through inhibition and 
potentiates the effects of GABA, which may contribute to the anxiolytic effects of L-
theanine87. 
 
  
  
Anxiolytic Effects on Patients  
 
 Anxiolytic effects of L-theanine have been a recent topic of interest.  One study 
using Sprague-Dawley rats by Heese et al. examined the effects of L-theanine on 
alleviating anxiety and how it relates to the GABAA receptor
88. Through experiments 
with a BZD and a GABAAreceptor antagonist, flumazenil, the behavioral component of 
anxiety was analyzed88.  Heese et al. concluded that the anxiolytic effect of L-theanine 
does not occur through potentiation of the GABAA receptor, rather, it was shown that an 
additive effect of anxiolysis was promoted though concurrent administration of the BZD 
midazolam with L-theanine, including fine motor movements, providing further evidence 
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of the anxiolytic effects of L-theanine88.  
 
 Another study evaluating the effects of L-theanine on PTSD studied the changes in 
gene expression implicated in PTSD individuals through evaluation of the amygdala and 
hippocampus of Spague-Dawley rats89.  Using one-way ANOVA, 88 genes were studied, 
in which 17 had a significant effect size >0.13889.  3 genes in the hippocampal region and 
amygdala were considered statistically significant with a P<0.0589.  Using reverse 
transcriptase polymerase chain reaction (RT-PCR), Ceremuga et al. was able to ascertain 
substantial changes between groups implicated in a variety of anxiety and mood 
disorders, including DRD2 and DRD1A89.  Although the mechanisms related to the 
anxiolytic effects of L-theanine aren’t fully understood, it is speculated that the 
potentiation of GABA is the main biochemical mechanism responsible for the decrease in 
anxiety related symptoms87.  
 
 
  
Anxiety and Schizophrenia 
  
 An interesting correlate to psychiatric medicine is that there are many studies 
showing the significant anxiety of patients with schizophrenia90.  Often times, 
schizophrenic patients are administered antipsychotic medications which have negative 
side effects, with anxiety being one of the most common complaints among patients90.  
Additionally, anxiety is often a co-morbidity with schizophrenia, thus exacerbating the 
devastating effects anxiety can have on the patient, in which suicidal ideation and 
attempts are often significant risks posed to schizophrenic patients90.  As a result, recent 
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studies have shown the substantial attenuation of anxiety that L-theanine may provide, 
without the long-term consequences or negative side effects associated with conventional 
treatment modalities of BZDs.  
 
 Many of the medications in which schizophrenic patients take often have unwanted  
side effects, including negative symptoms of blunted affect, alogia and anhedonia, often 
referred to as SANS.   One study by Kardashev et al. suggested that augmenting 
treatment with L-theanine could drastically attenuate such negative symptoms. Utilizing 
pregnenolone with L-theanine was shown to offer a dramatic reduction in negative SANS 
symptoms, compared to placebo91. Interestingly, the use of pregnenolone and L-theanine 
was associated with a decrease in anxiety as related to symptoms of anxious mood and 
tension91.  
 
 
L-Theanine Effects on Mood and Cognition 
 
 One study by Tamano et al. focused on the impact L-theanine may have on 
recognition memory in young rats92.  Using 0.3% theanine solution after weaning young 
rats, object recognition memory was shown to be maintained in the theanine administered 
rats, compared to the control group92.  Levels of brain derived neurotrophic factor and 
nerve growth factor, both constituents of brain development, were shown to be 
substantially elevated in the hippocampus in the theanine administered group vs control 
group92. Their study implied the beneficial impact theanine administration had on the 
young rats, possibly improving development of the hippocampus92. 
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Studies on Measuring Cognitive Effects In Combination with Caffeine  
 
 Caffeine, one of the most commonly used stimulants in the world, affects the 
adenosine A1 and A2a receptors and has been implicated in increasing Ach and DA 
neurotransmission, NT’s which are association with cognition and arousal.  L-theanine 
through its proposed mechanisms of glutamate reuptake inhibition as well as the 
potentiation on the NT GABA, DA, and 5-HT, may have a modulatory effect of caffeine 
on its ability to enhance cognition87. 
 The combination of caffeine and L-theanine, as present naturally in green tea, has 
been shown to increase accuracy in cognition87.  This was most profound during the first 
hour post administration87.  Increases in attention task-switching was most noticeable 
during the first hour, with a slightly smaller effect in the second hour87.  The meta-
analysis of L-theanine in conjunction with caffeine also showed improvement on 
unisensory auditory attention, with significant improvement during the second hour87. 
One study by Einother et al. showed how the concomitant dosing of caffeine and L-
theanine with a relatively high dose of L-theanine (97mg) with a smaller dose of caffeine 
(40mg) showed a greater significance in improvement in reaction time the first hour93.  
Nevertheless, the administration of caffeine and L-theanine was shown to significantly 
improve attention on a switch task in comparison to a placebo,  demonstrating that 
concomitant administration has a positive effect in improving attention93. 
 The meta-analysis by Camfield et al. concluded that the  combination of L-theanine 
and caffeine increased attention switching accuracy for both the first and second hours, 
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and an improvement of unisensory visual attention accuracy was found following 
concomitant administration for the first hour postdose87.  Furthermore, an incremental 
enhancement of unisensory auditory attention accuracy was found following in the 
second hour post dose87.   Although pharmacological study of L-theanine in relation to its 
improvement on cognition with or without caffeine is a relatively new area of research, 
more research data would be helpful in validating the claims of current studies, as there is 
still limited amount of empirical data.  
 
 
 
 
 
 
Molecular Effects of Caffeine and L-Theanine: Attenuation of L-Theanine on  
 
Overstimulation 
 
 L-theanine, being structurally similar to glutamic acid, has been associated with an 
increase in release of DA, an inhibition of the reuptake of glutamate, and antagonist of 
hippocampal glutamate receptors, and increase in GABA concentrations, and an increase 
release of 5-HT in the hippocampus, hypothalamus, and striatum94.  Interestingly, L-
theanine is thought to interact with caffeine by decreasing serotonin levels that have been 
elevated from caffeine intake94.  Additionally, L-theanine tends to attenuate potential 
overstimulation caused by caffeine, as shown by its ability to lower blood pressure 
changes in response to stress94.  Thus, it is implicated that the overall moiety of L-
theanine on a variety of neurotransmitters, and its overlay of interaction of the molecular 
transduction of caffeine, is thought to tone-down overstimulation by caffeine.  This could 
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perhaps be the biological mechanism leading to a synergistic effect of caffeine and L-
theanine, as the effects on the CNS by L-theanine work in combination with caffeine to 
enhance cognition and alertness due to increases in the monoamines, as well as providing 
neuroprotective effects by L-theanine due to its modulation on the glutamate receptors94. 
 
 
  
Effects of L-Theanine on Alpha-Wave and Brain Function  
 
 A limited number of studies have shown that L-theanine, an herbal supplement 
known to help induce relaxation, increases alpha-wave brain activity through studies 
involving electroencephalography (EEG), indicative of a wakeful, relaxed state 94.  
Alpha-wave brain activity is also associated with enhanced performance under stress, 
increased creativity, improved learning and concentration, as well as decreased anxiety94.  
Thus, the apparent effect of increasing alpha-wave brain activity through measurement of 
EEG by L-theanine may be what causes the favorable psychologic outcomes of increased 
cognition, focus, and relaxation94. 
 
 
 
 
L-Theanine as a Treatment for Sleep Disorders in Patients Co-Morbid with Anxiety  
 
Disorders 
 
 Sleep deprivation is associated with an increased risk of various diseases, also 
causing a poor quality of life and socioeconomic consequences95.  Anxiolysis is a 
requisite in the induction of high-quality sleep, and the anxiolytic effects of L-theanine in 
its potential use as a natural sleep aid was studied by Rao et al95.  
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 Anxiolytic effects of L-theanine, as evidence by an increase in alpha – brain wave 
activity, have promoted the utility of L-theanine as a natural anxiolytic without the 
negative side effects of conventional pharmacological modalities.  Furthermore, utilizing 
a small dose of L-theanine, 200mg, Rao et al. provided evidence that the anxiolytic 
properties of L-theanine may improve sleep quality in patients not because of the sedative 
effects, but due to its anxiolytic properties associated with increased alpha-wave brain 
activity95.  The unique property of L-theanine in promoting relaxation without sedation 
suggests that it can promote sleep induction and improving the quality of sleep, without 
the groggy effects often produced by current over the counter and prescription 
treatments95.  The paradoxical effect of L-theanine promoting relaxation through the 
stimulation of alpha waves, but without the sedating effects provides substantial evidence 
of the potential use of L-theanine as a safe and natural sleep aid95. 
 One study by Barrett et al. investigated the current treatment modalities in children 
with ADHD who were comorbid with insomnia96.  It showed that although zolpidem and 
L-theanine exhibited poor response in reducing sleep latency and increasing total sleep 
time, L-theanine produced an increase in sleep efficiency96.  This could prove to be 
beneficial with the pediatric patient population who are administered stimulant 
medications to treat ADHD, as zolpidem is shown to have high levels of side effects and 
its compliance is lower in children and adolescents96.  Thus, it is recommended that 
further research be pursued on the pharmacologic modalities for individual who have 
ADHD-related sleep disorders, as well as additional studies on the potential of 
supplementing L-theanine to help improve sleep quality among ADHD patients.  
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Neuroprotective Effects of L-Theanine  
 
Ischemia  
 
 L-theanine has been implicated in providing neuroprotective effects, with possibly 
providing neuroprotection from ischemia97.  Zukhurova et al. investigated on the effects 
of postischemic administration of L-theanine (1 and 4mg/kg) administered at 3, 12, and 
24 hours post reperfusion, as well as the effects of L-theanine on brain injury induced by 
exogenous administration of NMDA receptor agonists during reperfusion97.   
After subjecting rats to 30 minutes of middle cerebral artery occlusion followed 
by 48 hour reperfusion, neurological deficits and infarct size were determined.  At 3 and 
12 hours after reperfusion, L-theanine was shown to substantially reduce the size of brain 
infarction97.  Furthermore, neurological status was improved with postischemic 
administration of L-theanine at 3, 12, and 24 hours after reperfusion97.  Additionally, 
intrastriatal injections of L-theanine (total dose of 800µg/kg) prevented brain injury 
caused by NMDA receptor agonists, further providing evidence on the neuroprotective 
effect of L-theanine induced by ischemia or by exogenous administration of glutamate 
receptor agonists97.   
 
 
 
 
Parkinson’s Disease 
 
 Not only is L-theanine implicated in neuroprotection resulting from ischemic 
effects and exogenous induction of glutamate receptor agonists, but Cho et al. 
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investigated the protective effect of L-theanine on nigrostriatal dopaminergic neurons in 
Parkinson’s disease98.  Using L-theanine as a protective agent in neurotoxicity induced 
from rotenone and dieldrin, known PD-related neurotoxicants, the study revealed doses 
of 500 microM reduced both rotenone and dieldrin-induced DNA fragmentation and 
apoptotic death in the cultured human dopaminergic cell line SH-SY5Y cells98.   
 Additionally, down-regulation of extracellular signal-regulated kinase (ERK 1/2) 
phosphorylation was substantially blocked with L-theanine administration. Lastly, the 
attenuation of L-theanine on the down-regulation of BDNF and glial cell line-derived 
neurotrophic factor (GDNF) provides even more evidence of L-theanine in providing 
neuroprotection against PD-related toxicants, warranting further research into the 
investigation of L-theanine as a prophylactic agent to reduce further damage in 
Parkinson’s disease patients with intention to improve the prognosis as well as possibly 
providing symptomatic relief from Parkinson’s disease-related symptoms.  
 
 
 
 
 
 
Alzheimer’s Disease 
  
There has been recent evidence for the possibly neuroprotective effects of L-
theanine on patients with Alzheimer’s disease.  Much pathologic evidence points to the 
Amyloid β (Aβ) Protein in mediating neurotoxicity and cell death in patients with 
Alzhiemer’s disease99.  The Aβ Protein accumulates abnormally in the cortex and 
hippocampus in the brain of AD patients –leading to the direct induction of protein-
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mediated neuronal cell death99.  The overactivation of the mitogen-activated protein 
kinase pathway (MAPK) and the nuclear factor κB (NF-κB) pathways are strongly 
implicated as central pathways in promoting neuronal cell apoptosis100,101.  Research 
validating that the inhibition of these pathways is currently limited and could be 
tremendously useful in the treatment of neurodegenerative diseases using L-
theanine102,103.  
 A study by Kim et al. investigated the effects of reactive oxygen species 
generated by Aβ and the neuroprotective effects of L-theanine through the attenuation of 
oxidative damage by Aβ104.  The study showed that oral administration of L-theanine for 
5 weeks, followed by injection of Aβ1-42, dramatically reduced memory impairment 
caused by Aβ1-42 in mice104.  Kim et al. hypothesized that the reduction in memory 
impairment may have been due to the significant reduction in Aβ1 levels and the 
concomitant Aβ1-42-induced neuronal cell death, both in the hippocampal region and the 
cortex of the brain104.  Furthermore, L-theanine inhibited extracellular signal-related 
kinase (ERK) and NF-kB, while also promoting a significant attenuation on oxidative 
protein and lipid damage and elevated glutathione levels in the brain104.  Such evidence 
of the reduction on oxidative damage, as well as attenuating pathways associated with 
neuronal cell apoptosis, warrants continued investigation on the potential use of L-
theanine for treatment in Alzhiemer’s disease.  
 
 
L-Theanine: Anxiolytic effects Which Could Benefit Other Medical Conditions 
   
Diabetes 
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 There is some evidence that L-theanine may be effective against diabetes mellitus 
induced neurogeneration.  The CNS is quite susceptible to subtle changes in glucose, and 
glucose fluctuations related to hyperglycemia can amplify oxidative stress on the brain105.  
Much research has been performed on the increased risk of the development of 
neurogenerative diseases among individuals with diabetes105.  As already demonstrated 
with the Kim et al. study,  L-theanine tends to promote the reduction in oxidative damage 
related to the CNS, and regular intake of L-theanine through the regular consumption of 
green tea has been implicated in not only improving DM-related complications, but also 
providing neuroprotective effects and antioxidant potential to improve cognition in DM 
patients105.  The neuroprotective effect caused by a variety of conditions warrants more 
research into the profound benefits of  L-theanine administration among individuals with 
DM or other neurodegenerative conditions. 
 
 
Hypertension 
 
A study by Yoto et al has shown not only the benefits of L-theanine on 
attenuation of anxiety, but also reducing blood pressure increases in high stress-response 
adults after performing mental tasks compared to placebo.   This evidence was consistent 
with the blood pressure reducing effect of L-theanine in another study by Rogers et al., in 
which L-theanine attenuated blood pressure increases resulting from caffeine intake106.  
Although stress may not be directly correlated with the development of hypertension, it is 
known that repeated elevations of blood pressure as a response to stress, can eventually 
lead to hypertension107.  In a sense, if L-theanine helps attenuate blood pressure responses 
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from stressful events or tasks, it could possibly be a therapeutic route to help prevent the 
development of hypertension108.   
 Thus, it is apparent that additional research on the relationship between anxiety, 
blood pressure changes, and the administration of L-theanine would be recommended to 
investigate the potential use of L-theanine in not only treating anxiety, but also as a 
potential dietary supplement or even a pharmacological modality used to treat 
hypertension.  
 
 
DISCUSSION 
 
Negative physiological responses, such as changes in blood pressure in response 
to anxiety, provide ample evidence of the utility in L-theanine as a potential therapeutic 
agent in psychiatric conditions of anxiety, mood disorders, a natural sleep aid, as well as 
providing neuroprotective effects in individuals with neurological disorders of 
Alzhiemer’s Disease, Parkinson’s disease, and dementia with implications of helping 
other pathologic conditions of diabetes and hypertension in patients who are co-morbid 
with such common medical conditions.  
 The initial studies found on L-theanine to be a natural anxiolytic with potential 
implications in its use for psychiatric conditions where co-morbidities often exist, show 
positive results with great therapeutic potential.  The widespread utility of L-theanine, a 
rather non-toxic, non-essential amino acid found mainly in the C. sinesis green tea leaves, 
provides much support in its ability to attenuate anxiety in schizophrenic patients, and 
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improving cognition in patients, with or without co-morbidities of ADHD, depression, 
and PTSD.  
 The relaxation-promoting effects through the stimulation of alpha-wave brain 
activity provides opportunity for a multitude of uses, from as a natural sleep aid, to an 
increase in cognition in individuals who have ADHD and/or are co-morbid for anxiety 
disorders.  Additionally, individuals looking for a natural way to induce alpha-wave 
activity for relaxation and improvement of cognition could use L-theanine as a natural 
supplement.  
 Current pharmacologic modalities which are considered gold-standard in 
treatment of anxiety, such as BZDs, have known long-term negative effects, including 
effects on cognition, as well as the potential for abuse and physical and psychological 
dependency. Thus, BZDs should be prescribed with caution, as the apparent long-term 
use associated with them are apparent.  Without a doubt, such pharmacologic agents are 
known to have negative effects on cognitive function, especially in the elderly, with not a 
promise of such individuals returning to baseline function.  Furthermore, such agents 
have a tendency to be potentially abused among patient populations, and if it were 
possible to treat such anxiety disorders with a relatively non-toxic, non-addictive amino 
acid, it seems that research in comparing the utility of L-theanine and BZDs holds 
credibility with potential to have a greatly positive impact on patient populations in the 
medical community.  
 Since the number of studies available on the pharmacodynamic effects of L-
theanine are very limited, it is recommended that further elucidation of the molecular 
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mechanisms which cause the favorable clinical effects known thus far of L-theanine 
would be recommended.  If we are able to hone and ascertain more about the biology of 
specific psychiatric conditions of anxiety and mood disorders in their relation to L-
theanine, the potential for L-theanine not only as a natural sleep aid or herbal supplement 
with relaxative and focusing properties would not only be validated, but warrant the true 
potential as a legitimate psychotropic modality in the field of not only psychiatry, but 
other fields as well in which the concomitant use of BZDs is pertinent, such as the elderly 
population who may be seen regularly by a primary care physician.   
 The specificity in the need of a non-toxic, non-addictive anxiolytic with little 
effect on the cognitive function of patients proves to be of great utility.  Furthermore, 
understanding the neuroprotective effects of L-theanine promotes another realm of 
scientific research which has great implications for improving the betterment of the 
patient populations involving Alzheimer’s disease, dementia, and Parkinson’s disease.   
An overwhelming majority of the patient population affected by dementia and 
Alzhiemer’s disease tends to be within the elderly, giving a dual benefit in individuals 
suffering from both neurologic conditions as well as anxiety disorders.  Thus, it seems 
with exigence that further research into understanding the biologic origins and effects of 
L-theanine on this patient demographic proves to be extremely useful and worthwhile.   
  It should be noted that the potential utility of L-theanine in treating neurologic 
and psychiatric conditions warrants further research and investigation.  Additionally, the 
widespread effects of L-theanine have yet to be determined, and initial studies have 
shown the potential for L-theanine to be used as an adjunct treatment in modulating 
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chemotherapy and hyperlipidemia.  The wide potential uses of L-theanine not only apply 
to the realm of neurologic and psychiatric medicine, but also for a plethora of other 
medical conditions.   
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Elite Medical Scribes 
Medical Scribe February 2016 - current 
 
 Provide real‐time charting for physicians by shadowing them throughout their shifts 
and performing a variety of tasks, including recording patients' histories and chief 
complaints, transcribing physical exams, ordering x‐rays, recording diagnostic test 
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